LUCD
Lucid Diagnostics Inc.1.1200
+0.0100+0.9%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
146.83MP/E (TTM)
-Basic EPS (TTM)
-0.77Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Lucid Diagnostics posted Q3 revenue of $1.2M, up 3% y/y from $1.2M yet flat q/q, with YTD $3.2M (+2% y/y); gross margins held steady as costs ticked down slightly to $1.7M. Operating loss narrowed to $11.8M (-1% y/y) on lower R&D, while net loss improved to $10.4M (-16% y/y) thanks to a $2.3M gain from fair value drop on its $22.3M senior secured convertible notes (12% rate, due 2029). Cash swelled to $47.3M after $59M in equity raises, funding $33.9M operating burn. Diluted EPS of -$0.10 reconciles cleanly to 108M shares. Equity dilution marches on.
8-K
Q3 revenue up; Medicare win
Lucid Diagnostics reported Q3 2025 results, processing 2,841 EsoGuard tests for $1.2 million revenue amid $13.0 million operating expenses and $10.4 million net loss. Medicare experts unanimously backed coverage in September's MolDx CAC meeting, a pivotal LCD step. Cash swelled to $47.3 million post $27.0 million offering. Runway lasts through 2026.
8-K
Palumbo joins Lucid board
Lucid Diagnostics appointed healthcare veteran John R. Palumbo as Class B director effective September 22, 2025, designated by holders of its 12% Convertible Secured Promissory Notes due 2029. Palumbo brings 40 years scaling ventures to Fortune 100 firms, including IPOs and multibillion-dollar platforms. His network bolsters commercial push. Board adds convertible noteholder voice.
8-K
Offering closes with $26.9M net
8-K
Priced $25M stock offering
Lucid Diagnostics priced a public offering of 25 million common shares at $1.00 each on September 10, 2025, expecting $25 million gross proceeds before discounts. Closing set for September 11, subject to conditions; underwriters get a 30-day option for 3.75 million more shares. Funds target working capital. Dilution hits shareholders hard.
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BJDX
Bluejay Diagnostics, Inc.
0.97-0.04
BMRA
Biomerica, Inc.
2.37-0.08
CODX
Co-Diagnostics, Inc.
0.25-0.02
CSDX
CS Diagnostics Corp.
0.23-0.02
CV
CapsoVision, Inc.
12.00-1.78
GTHP
Guided Therapeutics, Inc.
0.25-0.02
LUDG
Ludwig Enterprises, Inc.
0.06+0.00
PAVM
PAVmed Inc.
0.31-0.01
RPID
Rapid Micro Biosystems, Inc.
3.52+0.05